Ambrx Biopharma Inc-adr (AMAM)

$11.5

+0.3

(+2.68%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Ambrx Biopharma Inc-adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 24.0K → 1.12M (in $), with an average increase of 97.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -15.15M → -17.82M (in $), with an average decrease of 17.6% per quarter

Performance

  • $11.03
    $11.55
    $11.50
    downward going graph

    4.09%

    Downside

    Day's Volatility :4.5%

    Upside

    0.43%

    downward going graph
  • $0.38
    $16.86
    $11.50
    downward going graph

    96.7%

    Downside

    52 Weeks Volatility :97.75%

    Upside

    31.79%

    downward going graph

Returns

PeriodAmbrx Biopharma Inc-adrSector (Health Care)Index (Russel 2000)
3 Months
-30.13%
-3.0%
0.0%
6 Months
28.35%
0.5%
0.0%
1 Year
964.81%
6.3%
6.3%
3 Years
-46.06%
22.1%
17.3%

Highlights

Market Capitalization
877.4M
Book Value
$4.06
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.27
Wall Street Target Price
23.67
Profit Margin
0.0%
Operating Margin TTM
-940.86%
Return On Assets TTM
-14.39%
Return On Equity TTM
-30.41%
Revenue TTM
5.6M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
-13.5%
Gross Profit TTM
7.4M
EBITDA
-52.1M
Diluted Eps TTM
-1.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.51
EPS Estimate Next Year
-0.5
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Ambrx Biopharma Inc-adr(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
8
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 105.83%

Current $11.50
Target $23.67

Company Financials

FY19Y/Y Change
Revenue
10.3M
-
Net Income
-20.1M
-
Net Profit Margin
-194.57%
-
FY20Y/Y Change
Revenue
13.7M
↑ 32.59%
Net Income
-16.5M
↓ 17.54%
Net Profit Margin
-121.01%
↑ 73.56%
FY21Y/Y Change
Revenue
7.5M
↓ 45.47%
Net Income
-68.1M
↑ 311.53%
Net Profit Margin
-913.2%
↓ 792.19%
FY22Y/Y Change
Revenue
7.4M
↓ 0.71%
Net Income
-78.0M
↑ 14.57%
Net Profit Margin
-1.1K%
↓ 140.52%
Q3 FY22Q/Q Change
Revenue
2.2M
-
Net Income
-13.3M
-
Net Profit Margin
-590.36%
-
Q4 FY22Q/Q Change
Revenue
7.4M
↑ 229.71%
Net Income
-78.0M
↑ 488.49%
Net Profit Margin
-1.1K%
↓ 463.36%
Q1 FY23Q/Q Change
Revenue
24.0K
↓ 99.68%
Net Income
-15.2M
↓ 80.57%
Net Profit Margin
-63.2K%
↓ 62096.28%
Q2 FY23Q/Q Change
Revenue
1.1M
↑ 4579.17%
Net Income
-17.8M
↑ 17.62%
Net Profit Margin
-1.6K%
↑ 61562.64%
FY19Y/Y Change
Total Assets
61.7M
-
Total Liabilities
28.3M
-
FY20Y/Y Change
Total Assets
134.0M
↑ 117.12%
Total Liabilities
273.5M
↑ 866.17%
FY21Y/Y Change
Total Assets
229.0M
↑ 70.88%
Total Liabilities
39.1M
↓ 85.72%
FY22Y/Y Change
Total Assets
147.0M
↓ 35.82%
Total Liabilities
29.1M
↓ 25.41%
Q2 FY22Q/Q Change
Total Assets
180.9M
-
Total Liabilities
39.0M
-
Q4 FY22Q/Q Change
Total Assets
147.0M
-
Total Liabilities
29.1M
-
Q1 FY23Q/Q Change
Total Assets
210.6M
↑ 43.3%
Total Liabilities
28.0M
↓ 3.8%
Q2 FY23Q/Q Change
Total Assets
279.9M
↑ 32.92%
Total Liabilities
29.6M
↑ 5.51%
FY19Y/Y Change
Operating Cash Flow
-2.8M
-
Investing Cash Flow
-48.0K
-
Financing Cash Flow
95.7M
-
FY20Y/Y Change
Operating Cash Flow
-20.6M
↑ 644.16%
Investing Cash Flow
-252.0K
↑ 425.0%
Financing Cash Flow
95.7M
↑ 0.0%
FY21Y/Y Change
Operating Cash Flow
-44.6M
↑ 116.95%
Investing Cash Flow
-3.2M
↑ 1172.22%
Financing Cash Flow
127.4M
↑ 33.18%
Q3 FY21Q/Q Change
Operating Cash Flow
-13.7M
↑ 59.63%
Investing Cash Flow
-809.5K
↑ 2.02%
Financing Cash Flow
16.0M
↓ 66.55%
Q4 FY21Q/Q Change
Operating Cash Flow
-13.7M
↑ 0.0%
Investing Cash Flow
-809.5K
↑ 0.0%
Financing Cash Flow
16.0M
↑ 0.0%
Q1 FY22Q/Q Change
Operating Cash Flow
-20.1M
↑ 46.45%
Investing Cash Flow
-32.1M
↑ 3865.66%
Financing Cash Flow
-17.0K
↓ 100.11%
Q2 FY22Q/Q Change
Operating Cash Flow
-20.1M
↑ 0.0%
Investing Cash Flow
-32.1M
↑ 0.0%
Financing Cash Flow
-17.0K
↑ 0.0%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ambrx Biopharma Inc-adr
Ambrx Biopharma Inc-adr
-18.79%
28.35%
964.81%
-46.06%
-46.06%
Moderna, Inc.
Moderna, Inc.
-11.43%
-29.94%
-12.65%
45.99%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.44%
1.41%
19.47%
47.01%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.29%
15.05%
82.56%
161.96%
290.64%
Seagen, Inc.
Seagen, Inc.
2.56%
4.47%
55.05%
8.41%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.86%
11.4%
20.1%
27.79%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ambrx Biopharma Inc-adr
Ambrx Biopharma Inc-adr
1.36
NA
NA
-0.51
-0.3
-0.14
0.0
4.06
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ambrx Biopharma Inc-adr
Ambrx Biopharma Inc-adr
Buy
$877.4M
-46.06%
1.36
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • Darwin Global Management, Ltd.

    26.91%

  • Cormorant Asset Management, LLC

    15.51%

  • D. E. Shaw & Co LP

    6.48%

  • COMMODORE CAPITAL LP

    5.12%

  • VR Adviser, LLC

    4.01%

  • Farallon Capital Management, L.L.C.

    3.66%

Company Information

ambrx, inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. at ambrx, we are dedicated to assembling and developing an exceptional team and a breakthrough technology to create the next generation of protein-based medicines.

Organization
Ambrx Biopharma Inc-adr
Employees
79
CEO
Ms. Sonja Nelson CPA
Industry
Healthcare

Discover More

FAQs